PDCD1 and neoplasm: Concomitant treatment increased tumor necrosis and significantly decreased the viable component of the tumor (Fig. 2C, where all the numerous post hoc between-group differences are shown, and Fig. S4A in Supplementary Material), achieving the greatest tumor regression, which was superior to that achieved by anti-PD-1 → cisplatin sequential treatment.